tbuckley/cabot-search huggingface dataset:
Outcomes of long responders chemorefractory metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib: a single institution experience
Authors: V. Sforza, A. Capasso, A. Nappi, C. Cardone, G. Martini, M.L. Ferrara, S. Napolitano, P. Vitiello, P. Vitale, N. Zanaletti, F. De Vita, M. Orditura, T. Troiani, F. Ciardiello, E. Martinelli
Journal: Annals of Oncology (2016)
Annals Story Slam - Curiosity and Compassion
Authors: Abigail Kay
Journal: Annals of Internal Medicine (2017)

Web Exclusives7 February 2017Annals On Being a Doctor Story Slam - Curiosity and CompassionFREEAbigail Kay, MDAbigail Kay, MDFrom Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W17-0015 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Curiosity and Compassion "Curiosity and Compassion," by Abigail Kay, MD (Duration 5:50)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: From Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.Current Author Address: Abigail Kay, MD, Thomas Jefferson University Hospital, Philadelphia, PA; e-mail, Abigail.[email protected]edu. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 February 2017Volume 166, Issue 3Page: SS1 ePublished: 7 February 2017 Issue Published: 7 February 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.Loading ...
EXTH-03. HUMAN GLIOMA CELL MIGRATION AND INVASION PROPERTIES ARE INHIBITED BY EXPOSURE TO TUMOR TREATING FIELDS (TTFIELDS) IN VITRO
Authors: Rosa Schneiderman, Anna Shteingauz, Moshe Giladi, Tali Voloshin, Yaara Porat, Mijal Munster, Roni Blat, Eilon Kirson, Uri Weinberg, Yoram Palti
Journal: Neuro-Oncology (2016)
Drug discovery for Diamond-Blackfan anemia using reprogrammed hematopoietic progenitors
Authors: Sergei Doulatov, Linda T. Vo, Elizabeth R. Macari, Lara Wahlster, Melissa A. Kinney, Alison M. Taylor, Jessica Barragan, Manav Gupta, Katherine McGrath, Hsiang-Ying Lee, Jessica M. Humphries, Alex DeVine, Anupama Narla, Blanche P. Alter, Alan H. Beggs, Suneet Agarwal, Benjamin L. Ebert, Hanna T. Gazda, Harvey F. Lodish, Colin A. Sieff, Thorsten M. Schlaeger, Leonard I. Zon, George Q. Daley
Journal: Science Translational Medicine (2017)

A stem cell reprogramming approach enables disease modeling and drug discovery for a genetic blood disorder and uncovers a candidate therapeutic.
MRD Detection in Mantle Cell Lymphoma: Flow Cytometry Is Comparable to Consensus Primer IgH-PCR at Initial Staging, but Less Sensitive Than PCR after Combined Immuno-Chemotherapy.
Authors: Sebastian Boettcher, Matthias Ritgen, Reiner Siebert, Sebastian Buske, Martina Klingenberg, Michael Unterhalt, Wolfgang Hiddemann, Martin H. Dreyling, Michael Kneba, Christiane Pott
Journal: Blood (2005)
Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AF RANDOMISED ): an open-label randomised controlled trial
Authors: Rolf Wachter, Klaus Gröschel, Götz Gelbrich, Gerhard F Hamann, Pawel Kermer, Jan Liman, Joachim Seegers, Katrin Wasser, Anna Schulte, Falko Jürries, Anna Messerschmid, Nico Behnke, Sonja Gröschel, Timo Uphaus, Anne Grings, Tugba Ibis, Sven Klimpe, Michaela Wagner-Heck, Magdalena Arnold, Evgeny Protsenko, Peter U Heuschmann, David Conen, Mark Weber-Krüger
Journal: The Lancet Neurology (2017)
Stereotactic hypofractionated high-dose irradiation (STI) for stage I non-small cell lung cancer (NSCLC): Mature results in 300 cases of a Japanese multi-institutional study
Authors: H. Onishi, Y. Nagata, H. Shirato, K. Karasawa, K. Gomi, M. Hiraoka, T. Kimura, K. Hayakawa, M. Kokubo, Y. Takai
Journal: Journal of Clinical Oncology (2006)

7045 Background: With the increasing accuracy of localization for tumor-bearing areas using various new techniques, hypofractionated or single high-dose stereotactic irradiation (STI) has been actively investigated for stage I NSCLC in Japan. The current study retrospectively evaluated Japanese multi-institutional results for high-dose STI for stage I NSCLC. Methods: From 1993 to 2003, stereotactic three-dimensional treatment was performed using 3–10 non-coplanar dynamic arcs or 6–20 static ports for a total of 300 stage I (median age, 75 years; T1N0M0, n = 193; T2N0M0, n = 107) patients with primary NSCLC (adenocarcinoma, n = 138; squamous cell carcinoma, n = 129; and others, n = 33) in 14 institutions. Totally 190 patients were medically inoperable, and other 110 were medically operable but selected STI. A total dose of 18–75 Gy at the isocenter was administered in 1–22 fractions. Median calculated biological effective dose (BED) was 108 Gy (range, 57–180 Gy). Results: Median follow-up period of survivors was 38 months (range; 2–128 months). Pulmonary complications of NCI-CTC criteria (version 2.0) grade ≥ 3 were noted in 9 patients (3.0%). Local progression occurred in 44 patients (14.7%), and 5-year local control rate was high (86%) for BED ≥100 Gy (n = 227) compared to 67% for &lt;100 Gy (n = 73) (P &lt; 0.001). Overall 5-year survival rates of operable and inoperable patients were 65% and 37%, respectively. Overall 5-year survival rates in operable cases was high (74%) for BED ≥100 Gy (n = 85) compared to 37% for &lt;100 Gy (n = 24) (P &lt; 0.01). In a subset of operable patients irradiated with BED ≥100, 3-year locally progression-free survival rates was high (81%) for stage IA (n = 60) compared to 67% for stage IB (n = 23) (P &lt; 0.05) Conclusions: Local control and survival rates of STI for stage I NSCLC are better with BED ≥100 Gy compared to &lt;100 Gy. Survival rates in selected patients (medically operable, BED ≥100 Gy) were excellent, and potentially comparable to those of surgery. Stage IB patients displayed higher rate of local progression than stage IA. We have started multi-institutional prospective study for stage IA NSCLC with a schedule of total dose of 48 Gy in 4 fractions during 4–8 days. No significant financial relationships to disclose.
KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%
Authors: M. Reck, D. Rodríguez-Abreu, A.G. Robinson, R. Hui, T. Csoszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O'Brien, S. Rao, K. Hotta, M. Leiby, G.M. Lubiniecki, Y. Shentu, R. Rangwala, J.R. Brahmer
Journal: Annals of Oncology (2016)
TAX-TORC: An investigator initiated phase I study combining the dual mTORC1/2 inhibitor AZD2014 in combination with weekly paclitaxel in high-grade serous ovarian cancer
Authors: U. Banerji, B. Basu, J.F. Spicer, R. Wilson, E. Hall, R. Sundar, S. Kumar, Y. Wu, V. Coyle, S. Carreira, M. Parmar, J.C. Dawes, S. Banerjee, J.S. de Bono
Journal: Annals of Oncology (2016)
Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor buparlisib (BKM120) in recurrent glioblastoma.
Authors: Patrick Y. Wen, W. K. Alfred Yung, Ingo K. Mellinghoff, Shakti Ramkissoon, Brian Michael Alexander, Mikael L. Rinne, Howard Colman, Antonio Marcilio Padula Omuro, Lisa Marie DeAngelis, Mark R. Gilbert, John Frederick De Groot, Timothy Francis Cloughesy, Andrew S. Chi, Eudocia Quant Lee, Lakshmi Nayak, Tracy Batchelor, Susan Marina Chang, Michael Prados, David A. Reardon, Keith L. Ligon
Journal: Journal of Clinical Oncology (2014)

2019 Background: The PI3K pathway is activated in most GBMs and represents a potential therapeutic target. Buparlisib is an oral, pan-Class I PI3K inhibitor that enters the brain at therapeutic concentrations and inhibits the growth of U87 and GBM PDX models. Methods: The Ivy Consortium conducted a phase II study of buparlisib in recurrent GBM patients with activation of the PI3K pathway (mutation, homozygous deletion or loss of immunohistochemistry (IHC) of PTEN, PIK3CA or PIK3RI mutations, or detectable pAKT). Additional eligibility criteria included radiologic progression, 1st or 2nd relapse, > 18 yrs, KPS > 60, adequate bone marrow and organ function, no prior bevacizumab or enzyme-inducing antiepileptic drugs. Patients received buparlisib 100mg daily. The study consisted of 2 concurrent cohorts. In Cohort 1 (up to 15 patients) buparlisib was given for 8-12 days prior to surgery for recurrent disease. Patients underwent FDG PET, pharmacokinetic studies, and tumor obtained for drug concentrations and pharmacodynamic effects. In Cohort 2, 50 patients with unresectable GBM received buparlisib with a . primary endpoint of PFS6. Results: 13 patients have been enrolled into cohort 1, 50 into cohort 2. Treatment was well-tolerated with no grade 4 toxicities. Grade 3 toxicities were asymptomatic lipase elevation (6), rash (4), hyperglycemia (3), fatigue (4), elevated ALT/AST (2), and 1 each of depression, anxiety, hypophosphatemia, thrombocytopenia and lymphopenia. Analysis of tumor specimens from Cohort 1 showed reduction of pAKTS473 by IHC in 4/6 (67%) of evaluable patients. The combined cohorts showed minimal efficacy with median PFS of 1.8 months and median OS of 10.9 months. Best response was stable disease. Only 1 patient in each cohort achieved PFS6. Of the first 40 patients who underwent exome sequencing, there were 4 PIK3CA (10%), 2 PIK3R1 (5%), and 13 PTEN (33%) mutations. Patients with PTEN loss and or PI3K mutations paradoxically had a worse outcome. Conclusions: Buparlisib is well-tolerated in patients with recurrent GBM and achieves adequate tumor concentration to inhibit pAKTS473. However, single agent efficacy was minimal. Final correlation of tumor genotype with outcome will be presented.
Intensive Chemotherapy (High-Dose CHOP/ESHAP Regimen) Followed by Autologous Stem-Cell Transplantation (ASCT) in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL). Results of a Prospective Phase II Study from the GELCAB.
Authors: Armando Lopez-Guillermo, Santiago Mercadal, Javier Briones, Blanca Xicoy, Carme Pedro, Lourdes Escoda, Cristina Estany, Mireia Camos, Josep Maria Ribera, Rodrigo Martino, Emilio Montserrat
Journal: Blood (2005)
Overweight And Obese Inner City Asthmatics (BMI: 25-40 Kg/m2); High IgE (HC, 30-700 IU/ml) Vs. Low IgE (LC, <30 IU/ml) Cohorts
Authors: Muhammad Ahmad, Ahmad Arslan, Muhammad S. Aslam, Radha Dhingra, Edward S. Schulman
Journal: Journal of Allergy and Clinical Immunology (2017)
Activation of the Complement, Coagulation and Fibrinolysis Pathways after Nasal Allergen Challenge
Authors: Ryan S. Thwaites, Natasha C. Gunawardana, None Verena L. Broich, None Elizabeth H. Mann, Gaynor A. Campbell, Tanushree Tunstall, Sarah Lindsley, Catherine M. Hawrylowicz, Peter J.M. Openshaw, Trevor T. Hansel
Journal: Journal of Allergy and Clinical Immunology (2017)
Decrease in CA-19-9 after neoadjuvant chemoradiation therapy to predict survival in locally advanced pancreatic cancer.
Authors: Jaswinder Singh, Syed Faisal Jafri, Maninder Pabla, Bradley L. Freilich, Joe Cates, John M. Sheldon, David Shaeffer, Michael Connor, Raj Shah, Reed Cope, Niharika Rath, Michael Burt, Srijita Mukherjee, Unnati Parikh, Jennifer Wanpen Feeback
Journal: Journal of Clinical Oncology (2012)

12 Background: Pancreatic adenocarcinoma is among the most lethal of human cancers. Data on overall survival rates of patients treated in the community hospital setting are limited. The purpose of this retrospective data collection study was to assess the CA19-9 change during the neo-adjuvant treatment of locally advanced pancreatic cancer patients and whether this test predicts the overall survival (OS). This study was conducted within a high volume community hospital setting. Methods: Eligibility included cytological or histological evidence of locally advanced, unresectable, and borderline resectable adenocarcinoma of the pancreas, not amenable for surgical resection. Resectability was determined with EUS and CT scan/MRI and was discussed in the multi-disciplinary conference. Patients diagnosed before July 2009 were treated with continuous 5-FU 200mg/m 2 for 5 weeks with radiation of 1.8 Gy per daily fraction, for a total dose of 50.4 Gy over 5.5 weeks. Patients diagnosed after July 2009 received gemcitabine 400mg/m 2 intravenously (over 60 minutes) beginning on the first day of radiation therapy (before radiation), then weekly thereafter during radiation. Results: Data were abstracted on 64 patients (40 deceased; 24 alive) diagnosed between 6/2005 and 4/2011. The median age was 68 years (range 41-87), and 52% were male. The majority of patients (97%) were diagnosed by endoscopic ultrasound (EUS) with biopsy. At diagnosis, 56 (88%) patients were locally advanced unresectable (without metastasis) or borderline resectable; 49 of these had neoadjuvant treatment, and 13 were later resected. Median OS for all 64 patients was 45.4 weeks (95% CI: 29.6-61.3), with no significant differences in OS by sex of patient (p = 0.210) or smoking history (p = 0.625). Twenty-two patients (34%) had &gt;75% decreases in CA19-9 from baseline; median OS was 89.4 weeks in this group compared to 41.3 weeks in patients with changes in CA19-9 &lt;75% (p = 0.025). Conclusions: This trial demonstrates improved overall survival in patients with locally advanced pancreatic cancer, who had significant decrease in CA19-9 (&gt;75% decreases in CA19-9 from baseline) in response to neo-adjuvant chemotherapy and radiation.
A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck-CheckMate 651
Authors: A. Argiris, M. Gillison, R.L. Ferris, K. Harrington, T.K. Sanchez, C. Baudelet, W.J. Geese, J. Shaw, R. Haddad
Journal: Annals of Oncology (2016)
Cancer survivors in Mexico: Analyzing their experience.
Authors: Laura Suchil-Bernal, Ana Rodriguez-Velazquez, Oscar Galindo-Vazquez, Abelardo Meneses-Garcia
Journal: Journal of Clinical Oncology (2016)

262 Background: Every year the number of people diagnosed with cancer increases due to aging, population growth, and the increasing life expectancy rate in the general population. Survivors have to deal with the long-term side effects of treatment, as well as psychological disturbances, such as fear of cancer recurrence. Herein we present the results of a research project about the treatment side effects and psychosocial problems that cancer survivors in Mexico experience. Methods: In order to explore their experience as cancer survivors, 1240 participants from different parts of the country voluntarily replied a 32-item questionnaire. Results: Participants were primarily women (81%), with an average age of 55 years (20 to 91 years). 18% of the survivors were younger than 40 years old, whereas only 15% were 70 years or older. Most participants had a level of education beyond high-school (46%). The three types of cancer that were most commonly reported were: breast cancer (48%), cervical cancer (11%) and lymphoma (6.8%). The majority of the participant survivors (67%) were diagnosed with cancer 5 years ago or longer. Fatigue was the most common side effect (55%), followed by bone pain (45%) and skin changes (42%). 26% of the population experienced sexual dysfunction; 50% reported diminished interest in sex and 19% of female survivors expressed having pain during intercourse. Fear of cancer recurrence (60%) was the chief psychosocial concern of survivors; depression (55%) and anxiety (44%) were also reported. Furthermore, 55% of survivors indicated they had felt discriminated. Conclusions: This is the first report about matters affecting cancer survivors in Mexico. Further studies are required to explore survivors' main health problems in order to treat them within a multidisciplinary approach and to create specific assistance programs.
Two Novel Distinct Subtypes of Myeloid Neoplasms Molecularly Associated with Histone H3K36 Methylations
Authors: Yosaku Watatani, Yasunobu Nagata, Vera Grossmann, Yusuke Okuno, Tetsuichi Yoshizato, Yusuke Shiozawa, Genta Nagae, Kenichi Yoshida, Keisuke Kataoka, Susanne Schnittger, Masashi Sanada, Ayana Kon, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Tsuyoshi Nakamaki, Shuichi Miyawaki, Shigeru Chiba, Tamara Alpermann, Niroshan Nadarajah, Phillip Koeffler, Hans-Ulrich Klein, Martin Dugas, Hiroyuki Aburatani, Claudia Haferlach, Wolfgang Kern, Satoru Miyano, Lee-Yung Shih, Seishi Ogawa, Torsten Haferlach, Hideki Makishima
Journal: Blood (2015)
Dipeptidyl Peptidase-4 Induces Aortic Valve Calcification by Inhibiting Insulin-Like Growth Factor-1 Signaling in Valvular Interstitial Cells
Authors: Bongkun Choi, Sahmin Lee, Sang-Min Kim, Eun-Jin Lee, Sun Ro Lee, Dae-Hee Kim, Jeong Yoon Jang, Sang-Wook Kang, Ki-Up Lee, Eun-Ju Chang, Jae-Kwan Song
Journal: Circulation (2017)

Calcification of the aortic valve leads to increased leaflet stiffness and consequently to the development of calcific aortic valve disease. However, the underlying molecular and cellular mechanisms of calcification remain unclear. Here, we identified that dipeptidyl peptidase-4 (DPP-4, also known as CD26) increases valvular calcification and promotes calcific aortic valve disease progression.We obtained the aortic valve tissues from humans and murine models (wild-type and endothelial nitric oxide synthase-deficient-mice) and cultured the valvular interstitial cells (VICs) and valvular endothelial cells from the cusps. We induced osteogenic differentiation in the primary cultured VICs and examined the effects of the DPP-4 inhibitor on the osteogenic changes in vitro and aortic valve calcification in endothelial nitric oxide synthase-deficient-mice. We also induced calcific aortic stenosis in male New Zealand rabbits (weight, 2.5-3.0 kg) by a cholesterol-enriched diet+vitamin D2 (25 000 IU, daily). Echocardiography was performed to assess the aortic valve area and the maximal and mean transaortic pressure gradients at baseline and 3-week intervals thereafter. After 12 weeks, we harvested the heart and evaluated the aortic valve tissue using immunohistochemistry.We found that nitric oxide depletion in human valvular endothelial cells activates NF-κB in human VICs. Consequently, the NF-κB promotes DPP-4 expression, which then induces the osteogenic differentiation of VICs by limiting autocrine insulin-like growth factor-1 signaling. The inhibition of DPP-4 enzymatic activity blocked the osteogenic changes in VICs in vitro and reduced the aortic valve calcification in vivo in a mouse model. Sitagliptin administration in a rabbit calcific aortic valve disease model led to significant improvements in the rate of change in aortic valve area, transaortic peak velocity, and maximal and mean pressure gradients over 12 weeks. Immunohistochemistry staining confirmed the therapeutic effect of Sitagliptin in terms of reducing the calcium deposits in the rabbit aortic valve cusps. In rabbits receiving Sitagliptin, the plasma insulin-like growth factor-1 levels were significantly increased, in line with DPP-4 inhibition.DPP-4-dependent insulin-like growth factor-1 inhibition in VICs contributes to aortic valve calcification, suggesting that DPP-4 could serve as a potential therapeutic target to inhibit calcific aortic valve disease progression.
SURG-29. PERSONALIZING THE DECISION GROSS TOTAL RESECTION (GTR) IN NEURO-ONCOLOGY
Authors: Clark Chen, Ali Alattar, Alex Schupper, Michael Brandel, Jennifer Padwal, Brian Hirshman, Bob Carter
Journal: Neuro-Oncology (2016)

Since glial tumors are inherently infiltrative, microscopic total resection is not possible without significant morbidity. The efficacy of cyto-reduction through gross total resection (GTR) largely depends on the chemo-sensitivity of the remaining tumor. For instance, GTR of primary CNS lymphoma (PCNSL) is rarely desired. Since chemo-sensitivity differ depending on glioma histology, we hypothesized that the survival benefit of GTR differ accordingly. We identified patients who underwent surgery for WHO grade II diffuse astrocytoma (DA, n= 4,113), WHO grade III anaplastic astrocytoma (AA, n=2,755), glioblastoma (n=21,962), and oligodendroglioma (grade II n=2,378; grade III n=11,028) in the Surveillance, Epidemiology, and End Results Program (SEER, 1999-2012). Median survival and hazard ratio (HR) for dying from the disease after correction of pertinent clinical/demographic variables was determined as a function of GTR, and subtotal resection (STR). Pertinent results were assessed against published literature. Based on hazard ratio analysis, DA and AA patients derived the greatest survival benefit from GTR. The median survival for patients with DA who underwent GTR and STR were >60 and 48 months, respectively. The median survival for patients with AA who underwent GTR and STR were 54 and 24 months, respectively. Glioblastoma patients derived modest survival benefit from GTR, with median survival of 13 months for GTR patients and 9 months for STR patients. In contrast, for grade II or III oligodendrogliomas, survival of GTR patients did not significantly differ irrespective of the extent of resection. Meta-analysis of articles identified from a comprehensive search of the published literature yield results comparable to the SEER database. Our study suggest that surgeons should take tumor histopathology into account when deciding upon the extent of surgical resection of glial tumors and the critical need for real-time intra-operative histologic diagnosis.
Deregulated Activity of AML1/RUNX1 Cooperates with BCR-ABL to Immortalize Hematopoietic Progenitor Cells and Induces Blast Crisis-Like Disease of Chronic Myelogenous Leukemia in Mice,
Authors: Kiyoko Yamamoto, Shinobu Tsuzuki, Tomoki Naoe, Masao Seto
Journal: Blood (2011)
A Case Series of Eight Patients with Clinical Anaphylaxis in the Setting of Vincristine Administration
Authors: David A. Hill, Allison Barz, Joseph Sciasci, Sean P. O'Neill, Anne Reilly, Naomi Balamuth, Steven Seeholzer, Terri F. Brown-Whitehorn, Jonathan M. Spergel
Journal: Journal of Allergy and Clinical Immunology (2017)
Outcome of Patients (pts) with Therapy-Related De Novo Acute Myeloid Leukemia (t-de novo AML): Single Institution Experience
Authors: Koji Sasaki, Elias Jabbour, Hagop M. Kantarjian, Jorge E. Cortes, Guillermo Garcia-Manero, Gautam Borthakur, Sherry R. Pierce, Naveen Pemmaraju, Susan O'Brien, Farhad Ravandi
Journal: Blood (2014)
IL-10 Promoter Gene Polymorphism Associated with the Occurrence of Chronic GVHD and Its Clinical Course during Systemic Immunosuppressive Treatment for Chronic GVHD after Allogeneic Peripheral Blood Stem Cell Transplantation.
Authors: Dong Hwan Kim, Nan Young Lee, Sang Kyun Sohn, Jin Ho Baek, Jong Gwang Kim, Jung Lim Lee, Jang Soo Suh, Kun Soo Lee, Kyu Bo Lee
Journal: Blood (2004)